{
    "Rank": 697,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00971737",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "J0947"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "P30CA006973",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P30CA006973"
                        },
                        {
                            "SecondaryId": "JHOC-J0947"
                        },
                        {
                            "SecondaryId": "NA_00024527"
                        },
                        {
                            "SecondaryId": "GENENTECH-JHOC-J0947"
                        },
                        {
                            "SecondaryId": "CDR0000653173",
                            "SecondaryIdType": "Other Identifier",
                            "SecondaryIdDomain": "other"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer",
                "OfficialTitle": "A Randomized, Open-Label Comparative Study of Combination Therapy With Cyclophosphamide and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine With or Without Trastuzumab for the Treatment of Metastatic Breast Cancer That Does NOT Over-express HER-2/Neu"
            },
            "StatusModule": {
                "StatusVerifiedDate": "April 2019",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "July 2009"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "March 2016",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "March 2016",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "September 3, 2009",
                "StudyFirstSubmitQCDate": "September 3, 2009",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "September 4, 2009",
                    "StudyFirstPostDateType": "Estimate"
                },
                "ResultsFirstSubmitDate": "February 15, 2019",
                "ResultsFirstSubmitQCDate": "February 15, 2019",
                "ResultsFirstPostDateStruct": {
                    "ResultsFirstPostDate": "March 12, 2019",
                    "ResultsFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "April 10, 2019",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "April 24, 2019",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        }
                    ]
                }
            },
            "OversightModule": {},
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an effective immune response to kill tumor cells. Biological therapies, such as cyclophosphamide and trastuzumab, may increase the number of immune cells and make the immune response stronger. It is not yet known whether giving cyclophosphamide together with vaccine therapy is more effective with or without trastuzumab in treating patients with metastatic breast cancer.\n\nPURPOSE: This randomized phase II trial is studying the side effects of giving cyclophosphamide together with vaccine therapy and to see how well it works compared with giving cyclophosphamide and vaccine therapy together with trastuzumab in treating patients with metastatic breast cancer.",
                "DetailedDescription": "OBJECTIVES:\n\nPrimary\n\nTo evaluate the safety of cyclophosphamide-modulated vaccination with vs without trastuzumab in patients with breast cancer that does not overexpress HER-2/neu.\nTo compare the clinical benefit of cyclophosphamide-modulated vaccination with vs without trastuzumab in these patients.\nTo measure HER-2/neu-specific CD4+ and CD8+ T-cell immunity by delayed-type hypersensitivity (DTH) and ELISPOT.\nTo measure the pharmacodynamics of CD4+CD25+ regulatory T cells by flow cytometry.\n\nSecondary\n\nTo assess the impact of trastuzumab on immune priming in vivo by immunohistochemistry of vaccine-site biopsies at day +3 and day +7 of courses 1 and 3 on the two study arms, comparing cellular infiltrates to those seen in previous preclinical and clinical models.\nTo measure hTERT-specific CD8+ T-cell immunity by ELISPOT.\nTo characterize the peripheral-memory T-cell pool.\n\nTertiary\n\nTo determine baseline and change in vaccine site-draining lymph node immunohistology and gene expression profile.\nTo develop the tandem tetramer/CD107a cytotoxicity assay for HER-2/neu-specific CD8+ T cells.\nTo measure novel T-cell responses induced by trastuzumab and cyclophosphamide-modulated vaccination.\n\nOUTLINE: Patients are randomized to 1 of 2 treatment arms.\n\nArm I: Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\nArm II: Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nSkin punch and lymph node biopsies are collected at baseline and on days +3 and +7 of courses 1 and 3 for biomarker analysis.\n\nAfter completion of study treatment, patients are followed periodically."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "stage IV breast cancer",
                        "male breast cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "Randomized",
                    "DesignInterventionModel": "Parallel Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "63",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Cyclophosphamide and Vaccine only",
                            "ArmGroupType": "Active Comparator",
                            "ArmGroupDescription": "Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Biological: allogeneic GM-CSF-secreting breast cancer vaccine",
                                    "Drug: cyclophosphamide"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "Cyclophosphamide, Vaccine and Trastuzumab",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Biological: allogeneic GM-CSF-secreting breast cancer vaccine",
                                    "Biological: trastuzumab",
                                    "Drug: cyclophosphamide"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Biological",
                            "InterventionName": "allogeneic GM-CSF-secreting breast cancer vaccine",
                            "InterventionDescription": "Given intradermally",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Cyclophosphamide and Vaccine only",
                                    "Cyclophosphamide, Vaccine and Trastuzumab"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Biological",
                            "InterventionName": "trastuzumab",
                            "InterventionDescription": "Given IV",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Cyclophosphamide, Vaccine and Trastuzumab"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "cyclophosphamide",
                            "InterventionDescription": "Given IV",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Cyclophosphamide and Vaccine only",
                                    "Cyclophosphamide, Vaccine and Trastuzumab"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Toxicity as Assessed by Number of Grade 3 or 4 Adverse Events",
                            "PrimaryOutcomeDescription": "Number of grade 3 or 4 nonhematologic toxicity (except alopecia), or any grade 4 hematologic toxicity as defined by NCI CTCAE v3.0",
                            "PrimaryOutcomeTimeFrame": "3 years"
                        },
                        {
                            "PrimaryOutcomeMeasure": "Clinical Benefit (CB) as Assessed by Progression Free Survival at Six Months",
                            "PrimaryOutcomeDescription": "Progression-free survival is measured as percentage of participants with stable disease or complete response, as defined by RECIST criteria, six months after receiving last vaccination. Progressive disease (PD) will be defined by the appearance of a new lesion, or by an increase of at least 20% in the sum of the longest diameter of target lesions, taking as a reference that smallest sum longest diameter recorded since the study intervention began. In the case of bone lesions, progressive disease will be established after eight weeks of increasing or new lesions if there is subjective progressive disease as noted by increasing bone pain or decreasing performance status. These observations must be present for at least two measurement periods separated by at least four weeks.",
                            "PrimaryOutcomeTimeFrame": "6 months post-intervention"
                        },
                        {
                            "PrimaryOutcomeMeasure": "HER-2/Neu-specific Immune Responses as Measured by Number of Participants With Positive for Delayed-type Hypersensitivity (DTH) Response",
                            "PrimaryOutcomeTimeFrame": "3 years"
                        },
                        {
                            "PrimaryOutcomeMeasure": "Pharmacodynamics of Peripheral CD4+CD25+ Regulatory T Cells",
                            "PrimaryOutcomeTimeFrame": "3 years"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Immune Priming in In-vivo Vaccine-site Biopsies",
                            "SecondaryOutcomeTimeFrame": "3 years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Enumeration of CD8+ T Cells Specific for hTERT by ELISPOT",
                            "SecondaryOutcomeTimeFrame": "3 years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Characterization of the T-cell Memory Pool Pre- and Post-vaccination",
                            "SecondaryOutcomeTimeFrame": "3 years"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nHistologically confirmed adenocarcinoma of the breast\n\nDoes not overexpress HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC\nStage IV disease\nMust not be eligible for therapy of known curative potential for metastatic breast cancer\nMeasurable or evaluable disease\nStable CNS disease allowed provided that it's adequately treated and not under active treatment\nHormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\nMenopausal status not specified\nECOG performance status 0-1\nANC > 1,000/mm^3\nPlatelets > 100,000/mm^3\nSerum bilirubin < 2.0 mg/dL (unless due to Gilbert syndrome)\nAST and ALT < 2 times upper limit of normal (ULN)\nAlkaline phosphatase < 5 times ULN\nSerum creatinine < 2.0 mg/dL\nEjection fraction normal by MUGA OR \u2265 50% by echocardiogram\nNot pregnant or nursing\nFertile patients must use effective contraception\nHIV negative\nAsthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids allowed\n\nNo prior or concurrent autoimmune disease requiring management with systemic immunosuppression, including any of the following:\n\nInflammatory bowel disease\nSystemic vasculitis\nScleroderma\nPsoriasis\nMultiple sclerosis\nHemolytic anemia or immune-mediated thrombocytopenia\nRheumatoid arthritis\nSystemic lupus erythematosus\nSjogren syndrome\nSarcoidosis\nOther rheumatologic disease\nNo other malignancies within the past 5 years, except carcinoma in situ of the cervix, superficial nonmelanoma skin cancer, superficial bladder cancer, or tamoxifen-related endometrial cancer that has been adequately treated\nNo active major medical or psychosocial problems that could be complicated by study participation\nNo symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest\nNo uncontrolled medical problems\nNo evidence of active acute or chronic infection\nNo known severe hypersensitivity to trastuzumab, except mild to moderate infusion reactions that are easily managed and do not recur\nNo allergy to corn\n\nPRIOR CONCURRENT THERAPY:\n\nSee Disease Characteristics\n\nMore than 28 days since prior and no other concurrent chemotherapy, radiation therapy, or biologic therapy (except trastuzumab)\n\nConcurrent endocrine therapy and supportive therapy with bisphosphonates allowed\nMore than 28 days since prior and no other concurrent participation in an investigational new drug trial\n\nMore than 28 days since prior and no other concurrent systemic oral steroids\n\nTopical, ocular, and nasal steroids allowed\nNo prior vaccination with the allogeneic GM-CSF-secreting breast tumor vaccine",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "MaximumAge": "120 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Leisha A. Emens, MD, PhD",
                            "OverallOfficialAffiliation": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                            "LocationCity": "Baltimore",
                            "LocationState": "Maryland",
                            "LocationZip": "21231-2410",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "ResultsSection": {
            "ParticipantFlowModule": {
                "FlowPreAssignmentDetails": "3 subjects were withdrawn prior to receiving intervention (2 due to development of new medical problems, 1 due to anxiety and non-compliance).",
                "FlowGroupList": {
                    "FlowGroup": [
                        {
                            "FlowGroupId": "FG000",
                            "FlowGroupTitle": "Cyclophosphamide and Vaccine Only",
                            "FlowGroupDescription": "Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ncyclophosphamide: Given IV"
                        },
                        {
                            "FlowGroupId": "FG001",
                            "FlowGroupTitle": "Cyclophosphamide, Vaccine and Trastuzumab",
                            "FlowGroupDescription": "Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ntrastuzumab: Given IV\n\ncyclophosphamide: Given IV"
                        }
                    ]
                },
                "FlowPeriodList": {
                    "FlowPeriod": [
                        {
                            "FlowPeriodTitle": "Overall Study",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "30"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG001",
                                                    "FlowAchievementNumSubjects": "30"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "30"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG001",
                                                    "FlowAchievementNumSubjects": "30"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "0"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG001",
                                                    "FlowAchievementNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "BaselineCharacteristicsModule": {
                "BaselinePopulationDescription": "63 subjects were deemed eligible for this study. 2 were taken off-study prior to vaccination due to the development of new medical problems. 1 subject was taken off due to anxiety and non-compliance. 60 research subjects went on to receive at least 1 vaccination, where 30 subjects were randomized to Arm A and 30 subjects were randomized to Arm B.",
                "BaselineGroupList": {
                    "BaselineGroup": [
                        {
                            "BaselineGroupId": "BG000",
                            "BaselineGroupTitle": "Cyclophosphamide and Vaccine Only",
                            "BaselineGroupDescription": "Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ncyclophosphamide: Given IV"
                        },
                        {
                            "BaselineGroupId": "BG001",
                            "BaselineGroupTitle": "Cyclophosphamide, Vaccine and Trastuzumab",
                            "BaselineGroupDescription": "Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ntrastuzumab: Given IV\n\ncyclophosphamide: Given IV"
                        },
                        {
                            "BaselineGroupId": "BG002",
                            "BaselineGroupTitle": "Total",
                            "BaselineGroupDescription": "Total of all reporting groups"
                        }
                    ]
                },
                "BaselineDenomList": {
                    "BaselineDenom": [
                        {
                            "BaselineDenomUnits": "Participants",
                            "BaselineDenomCountList": {
                                "BaselineDenomCount": [
                                    {
                                        "BaselineDenomCountGroupId": "BG000",
                                        "BaselineDenomCountValue": "30"
                                    },
                                    {
                                        "BaselineDenomCountGroupId": "BG001",
                                        "BaselineDenomCountValue": "30"
                                    },
                                    {
                                        "BaselineDenomCountGroupId": "BG002",
                                        "BaselineDenomCountValue": "60"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "BaselineMeasureList": {
                    "BaselineMeasure": [
                        {
                            "BaselineMeasureTitle": "Age, Categorical",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "<=18 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Between 18 and 65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "27"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "25"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "52"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": ">=65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "3"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "5"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "8"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Age, Continuous",
                            "BaselineMeasureParamType": "Mean",
                            "BaselineMeasureDispersionType": "Full Range",
                            "BaselineMeasureUnitOfMeasure": "years",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "53",
                                                                "BaselineMeasurementLowerLimit": "25",
                                                                "BaselineMeasurementUpperLimit": "73"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "52",
                                                                "BaselineMeasurementLowerLimit": "34",
                                                                "BaselineMeasurementUpperLimit": "69"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "53",
                                                                "BaselineMeasurementLowerLimit": "25",
                                                                "BaselineMeasurementUpperLimit": "73"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sex: Female, Male",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Female",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "30"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "30"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "60"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Male",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Region of Enrollment",
                            "BaselineMeasureParamType": "Number",
                            "BaselineMeasureUnitOfMeasure": "participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineClassTitle": "United States",
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "30"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "30"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "60"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomeMeasuresModule": {
                "OutcomeMeasureList": {
                    "OutcomeMeasure": [
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Toxicity as Assessed by Number of Grade 3 or 4 Adverse Events",
                            "OutcomeMeasureDescription": "Number of grade 3 or 4 nonhematologic toxicity (except alopecia), or any grade 4 hematologic toxicity as defined by NCI CTCAE v3.0",
                            "OutcomeMeasurePopulationDescription": "Data was not evaluable in 2/30 participants from the cyclophosphamide and vaccine-only arm.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Number",
                            "OutcomeMeasureUnitOfMeasure": "adverse events",
                            "OutcomeMeasureTimeFrame": "3 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Cyclophosphamide and Vaccine Only",
                                        "OutcomeGroupDescription": "Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ncyclophosphamide: Given IV"
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Cyclophosphamide, Vaccine and Trastuzumab",
                                        "OutcomeGroupDescription": "Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ntrastuzumab: Given IV\n\ncyclophosphamide: Given IV"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "28"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "30"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Clinical Benefit (CB) as Assessed by Progression Free Survival at Six Months",
                            "OutcomeMeasureDescription": "Progression-free survival is measured as percentage of participants with stable disease or complete response, as defined by RECIST criteria, six months after receiving last vaccination. Progressive disease (PD) will be defined by the appearance of a new lesion, or by an increase of at least 20% in the sum of the longest diameter of target lesions, taking as a reference that smallest sum longest diameter recorded since the study intervention began. In the case of bone lesions, progressive disease will be established after eight weeks of increasing or new lesions if there is subjective progressive disease as noted by increasing bone pain or decreasing performance status. These observations must be present for at least two measurement periods separated by at least four weeks.",
                            "OutcomeMeasurePopulationDescription": "Data was not evaluable in 2/30 participants from the cyclophosphamide and vaccine-only arm.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Number",
                            "OutcomeMeasureDispersionType": "95% Confidence Interval",
                            "OutcomeMeasureUnitOfMeasure": "percentage of participants",
                            "OutcomeMeasureTimeFrame": "6 months post-intervention",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Cyclophosphamide and Vaccine Only",
                                        "OutcomeGroupDescription": "Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ncyclophosphamide: Given IV"
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Cyclophosphamide, Vaccine and Trastuzumab",
                                        "OutcomeGroupDescription": "Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ntrastuzumab: Given IV\n\ncyclophosphamide: Given IV"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "28"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "30"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "33",
                                                                "OutcomeMeasurementLowerLimit": "17",
                                                                "OutcomeMeasurementUpperLimit": "53"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "37",
                                                                "OutcomeMeasurementLowerLimit": "20",
                                                                "OutcomeMeasurementUpperLimit": "56"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "HER-2/Neu-specific Immune Responses as Measured by Number of Participants With Positive for Delayed-type Hypersensitivity (DTH) Response",
                            "OutcomeMeasurePopulationDescription": "Data was not evaluable in 2/30 participants from the cyclophosphamide and vaccine-only arm.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "3 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Cyclophosphamide and Vaccine Only",
                                        "OutcomeGroupDescription": "Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ncyclophosphamide: Given IV"
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Cyclophosphamide, Vaccine and Trastuzumab",
                                        "OutcomeGroupDescription": "Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ntrastuzumab: Given IV\n\ncyclophosphamide: Given IV"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "28"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "30"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "14"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "16"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Pharmacodynamics of Peripheral CD4+CD25+ Regulatory T Cells",
                            "OutcomeMeasurePopulationDescription": "Lab analysis could not be completed due to loss of funding, therefore data was not collected to assess this outcome measure.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "3 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Cyclophosphamide and Vaccine Only",
                                        "OutcomeGroupDescription": "Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ncyclophosphamide: Given IV"
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Cyclophosphamide, Vaccine and Trastuzumab",
                                        "OutcomeGroupDescription": "Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ntrastuzumab: Given IV\n\ncyclophosphamide: Given IV"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Immune Priming in In-vivo Vaccine-site Biopsies",
                            "OutcomeMeasurePopulationDescription": "Lab analysis could not be completed due to loss of funding, therefore data was not collected to assess this outcome measure",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "3 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Cyclophosphamide and Vaccine Only",
                                        "OutcomeGroupDescription": "Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ncyclophosphamide: Given IV"
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Cyclophosphamide, Vaccine and Trastuzumab",
                                        "OutcomeGroupDescription": "Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ntrastuzumab: Given IV\n\ncyclophosphamide: Given IV"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Enumeration of CD8+ T Cells Specific for hTERT by ELISPOT",
                            "OutcomeMeasurePopulationDescription": "Lab analysis could not be completed due to loss of funding, therefore data was not collected to assess this outcome measure.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "3 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Cyclophosphamide and Vaccine Only",
                                        "OutcomeGroupDescription": "Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ncyclophosphamide: Given IV"
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Cyclophosphamide, Vaccine and Trastuzumab",
                                        "OutcomeGroupDescription": "Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ntrastuzumab: Given IV\n\ncyclophosphamide: Given IV"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Characterization of the T-cell Memory Pool Pre- and Post-vaccination",
                            "OutcomeMeasurePopulationDescription": "Lab analysis could not be completed due to loss of funding, therefore data was not collected to assess this outcome measure.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "3 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Cyclophosphamide and Vaccine Only",
                                        "OutcomeGroupDescription": "Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ncyclophosphamide: Given IV"
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Cyclophosphamide, Vaccine and Trastuzumab",
                                        "OutcomeGroupDescription": "Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ntrastuzumab: Given IV\n\ncyclophosphamide: Given IV"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "AdverseEventsModule": {
                "EventsFrequencyThreshold": "0",
                "EventsTimeFrame": "up to 6 months post-intervention",
                "EventGroupList": {
                    "EventGroup": [
                        {
                            "EventGroupId": "EG000",
                            "EventGroupTitle": "Cyclophosphamide and Vaccine Only",
                            "EventGroupDescription": "Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ncyclophosphamide: Given IV",
                            "EventGroupDeathsNumAffected": "0",
                            "EventGroupDeathsNumAtRisk": "30",
                            "EventGroupSeriousNumAffected": "0",
                            "EventGroupSeriousNumAtRisk": "30",
                            "EventGroupOtherNumAffected": "30",
                            "EventGroupOtherNumAtRisk": "30"
                        },
                        {
                            "EventGroupId": "EG001",
                            "EventGroupTitle": "Cyclophosphamide, Vaccine and Trastuzumab",
                            "EventGroupDescription": "Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.\n\nallogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally\n\ntrastuzumab: Given IV\n\ncyclophosphamide: Given IV",
                            "EventGroupDeathsNumAffected": "0",
                            "EventGroupDeathsNumAtRisk": "30",
                            "EventGroupSeriousNumAffected": "0",
                            "EventGroupSeriousNumAtRisk": "30",
                            "EventGroupOtherNumAffected": "30",
                            "EventGroupOtherNumAtRisk": "30"
                        }
                    ]
                },
                "OtherEventList": {
                    "OtherEvent": [
                        {
                            "OtherEventTerm": "Erythema/swelling of vaccine sites",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "82",
                                        "OtherEventStatsNumAffected": "30",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "102",
                                        "OtherEventStatsNumAffected": "30",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pain/soreness/tenderness of vaccine sites",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "81",
                                        "OtherEventStatsNumAffected": "28",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "82",
                                        "OtherEventStatsNumAffected": "30",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pruritus of vaccine sites",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "78",
                                        "OtherEventStatsNumAffected": "30",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "92",
                                        "OtherEventStatsNumAffected": "30",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Rash around vaccine sites",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Blister at vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "28",
                                        "OtherEventStatsNumAffected": "16",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "41",
                                        "OtherEventStatsNumAffected": "20",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Ecchymosis at vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "10",
                                        "OtherEventStatsNumAffected": "8",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "24",
                                        "OtherEventStatsNumAffected": "18",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hyperpigmentation at vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Warmth at vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "26",
                                        "OtherEventStatsNumAffected": "16",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "34",
                                        "OtherEventStatsNumAffected": "17",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Anorexia",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "22",
                                        "OtherEventStatsNumAffected": "13",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "17",
                                        "OtherEventStatsNumAffected": "10",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Aphthus Ulcers",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Arthralgia",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "32",
                                        "OtherEventStatsNumAffected": "15",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "33",
                                        "OtherEventStatsNumAffected": "19",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Bruising",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Chills",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "29",
                                        "OtherEventStatsNumAffected": "16",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "27",
                                        "OtherEventStatsNumAffected": "15",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Constipation",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dermatographism",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Diarrhea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dizziness",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dry throat",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Eczema",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Erythema",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Fatigue",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "34",
                                        "OtherEventStatsNumAffected": "16",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "32",
                                        "OtherEventStatsNumAffected": "18",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Fever",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "18",
                                        "OtherEventStatsNumAffected": "11",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "17",
                                        "OtherEventStatsNumAffected": "11",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Flatulence",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Flu-like symptoms",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Headache",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "21",
                                        "OtherEventStatsNumAffected": "11",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "18",
                                        "OtherEventStatsNumAffected": "15",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hypotension",
                            "OtherEventOrganSystem": "Cardiac disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Indigestion",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Infection, Herpes",
                            "OtherEventOrganSystem": "Infections and infestations",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Insomnia",
                            "OtherEventOrganSystem": "Psychiatric disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "8",
                                        "OtherEventStatsNumAffected": "6",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Lymphadenopathy",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "14",
                                        "OtherEventStatsNumAffected": "9",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "31",
                                        "OtherEventStatsNumAffected": "19",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Malaise",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Mucositis",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Myalgia",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "41",
                                        "OtherEventStatsNumAffected": "16",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "37",
                                        "OtherEventStatsNumAffected": "22",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Nausea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "16",
                                        "OtherEventStatsNumAffected": "12",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "10",
                                        "OtherEventStatsNumAffected": "8",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Neck stiffness",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pain, bone",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pain, hip/groin",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pruritis",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Rash",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "10",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "12",
                                        "OtherEventStatsNumAffected": "9",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Sweats",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Urticaria",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Vaccine flare",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Vomiting",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hives",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "9",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "30"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "MoreInfoModule": {
                "CertainAgreement": {
                    "AgreementPISponsorEmployee": "Yes"
                },
                "PointOfContact": {
                    "PointOfContactTitle": "Leisha Emens, MD, PhD",
                    "PointOfContactOrganization": "Johns Hopkins University",
                    "PointOfContactEMail": "emensle@jhmi.edu"
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M20355",
                            "ConditionBrowseLeafName": "Breast Neoplasms, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T861",
                            "ConditionBrowseLeafName": "Breast Cancer, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000003520",
                            "InterventionMeshTerm": "Cyclophosphamide"
                        },
                        {
                            "InterventionMeshId": "D000068878",
                            "InterventionMeshTerm": "Trastuzumab"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000007166",
                            "InterventionAncestorTerm": "Immunosuppressive Agents"
                        },
                        {
                            "InterventionAncestorId": "D000007155",
                            "InterventionAncestorTerm": "Immunologic Factors"
                        },
                        {
                            "InterventionAncestorId": "D000045505",
                            "InterventionAncestorTerm": "Physiological Effects of Drugs"
                        },
                        {
                            "InterventionAncestorId": "D000018501",
                            "InterventionAncestorTerm": "Antirheumatic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000018906",
                            "InterventionAncestorTerm": "Antineoplastic Agents, Alkylating"
                        },
                        {
                            "InterventionAncestorId": "D000000477",
                            "InterventionAncestorTerm": "Alkylating Agents"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000019653",
                            "InterventionAncestorTerm": "Myeloablative Agonists"
                        },
                        {
                            "InterventionAncestorId": "D000074322",
                            "InterventionAncestorTerm": "Antineoplastic Agents, Immunological"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M17050",
                            "InterventionBrowseLeafName": "Vaccines",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M325",
                            "InterventionBrowseLeafName": "Trastuzumab",
                            "InterventionBrowseLeafAsFound": "Via",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M6417",
                            "InterventionBrowseLeafName": "Cyclophosphamide",
                            "InterventionBrowseLeafAsFound": "Time",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M9902",
                            "InterventionBrowseLeafName": "Immunosuppressive Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9891",
                            "InterventionBrowseLeafName": "Immunologic Factors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M20294",
                            "InterventionBrowseLeafName": "Antirheumatic Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M20632",
                            "InterventionBrowseLeafName": "Antineoplastic Agents, Alkylating",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3510",
                            "InterventionBrowseLeafName": "Alkylating Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M1346",
                            "InterventionBrowseLeafName": "Antineoplastic Agents, Immunological",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "ARhu",
                            "InterventionBrowseBranchName": "Antirheumatic Agents"
                        }
                    ]
                }
            }
        }
    }
}